AI주식인사이트AI Stock Insight
C

현대바이오랜드

052260KOSDAQ

53.0 / 100

Reference Date: 2026-10-23

Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 8.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hyundai BioLand operates in various sectors including cosmetics, health supplements, pharmaceutical ingredients, medical devices, and brand distribution, leveraging natural bio-materials. The company focuses on developing high-value products such as hyaluronic acid and plant-based collagen, while expanding global partnerships. It emphasizes R&D to meet environmental regulations and consumer trends, and is actively growing its market presence through innovative technologies and strategic collaborations.

Number of Employees

342people

Average Salary

66.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
544.38Industry Average 15.000.0Point

36.3x industry avg (risky)

PBR
0.96Industry Average 1.204.0Point

In line with industry avg

ROE
0.18Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
1.84Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲54.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.5% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (46%)

Current 4,355Won52-week high 5,67052-week low 3,225
1-month return5.0Point

1m +8.88% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0